Company intelligence / Profile preview

PuriBlood

Hsinchu City / Baoshan Township, Hsinchu City, Taiwanpuriblood.com ↗

Ownership: Private
Employees: ~42
Development stage: Commercial

Overview

PuriBlood has developed and commercialized a proprietary membrane-based leukocyte reduction filter set, using its patented ZISC technology. The company is Taiwan’s only domestic producer of leukocyte filter blood bags and has expanded internationally, including partnerships in Brazil. Clinical results are not detailed in public sources but the product is commercially available and used in clinical settings.

Therapeutic areas: Hematology
Modalities: Device (blood filtration/leukoreduction filter sets)Material technology (Zwitterionic-bias Surface Coating Technology, ZISC)
Industry: Consumable Medical Devices

Partnerships

ABHH (Brazilian Association of Hematology, Hemotherapy and Cellular Therapy)Cromo Produtos Médicos S.A. [Brazil distribution partner]

Beyond the preview

Go deeper on PuriBlood.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PuriBlood.

Explore the full profile